Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Herpesviridae Infections

ClinicalTrials.gov lists 2,415 trials for Herpesviridae Infections or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 152.

MeSH D006566 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 537 Phase 1/2 Phase 1/2 197 Phase 2 Phase 2 531 Phase 2/3 Phase 2/3 31 Phase 3 Phase 3 300 Phase 4 Phase 4 131 Not applicable Not applicable 308 Observational Observational 372 Phase 1 Phase 1 537 Phase 1/2 Phase 1/2 197 Phase 2 Phase 2 531 Phase 2/3 Phase 2/3 31 Phase 3 Phase 3 300 Phase 4 Phase 4 131 Not applicable Not applicable 308 Observational Observational 372

Trials per phase

2 more sections with rows

28 of the 2,415 trials are tagged with Herpesviridae Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Herpesviridae Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Herpesviridae Infections trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 125

1990: 6 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 3) 1991: 3 trials (Phase 3 1, Phase 2 2) 1992: 16 trials (Observational 3, Phase 3 5, Phase 2 6, Phase 1 2) 1993: 6 trials (Observational 1, Phase 2 4, Phase 1 1) 1994: 6 trials (Not applicable 1, Phase 2/3 1, Phase 2 2, Phase 1 2) 1995: 18 trials (Observational 2, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 4, Phase 1 3) 1996: 23 trials (Observational 6, Phase 3 3, Phase 2 7, Phase 1 7) 1997: 43 trials (Observational 2, Not applicable 3, Phase 3 12, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 12) 1998: 47 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 17, Phase 1/2 3, Phase 1 16) 1999: 58 trials (Observational 5, Not applicable 3, Phase 3 10, Phase 2 12, Phase 1/2 5, Phase 1 23) 2000: 61 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 3 10, Phase 2 20, Phase 1/2 3, Phase 1 18) 2001: 37 trials (Observational 5, Not applicable 4, Phase 4 2, Phase 3 3, Phase 2 11, Phase 1/2 2, Phase 1 10) 2002: 47 trials (Observational 4, Not applicable 6, Phase 4 2, Phase 3 6, Phase 2 12, Phase 1/2 3, Phase 1 14) 2003: 56 trials (Observational 4, Not applicable 7, Phase 4 4, Phase 3 9, Phase 2 16, Phase 1/2 6, Phase 1 10) 2004: 73 trials (Observational 7, Not applicable 8, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 19, Phase 1/2 3, Phase 1 19) 2005: 76 trials (Observational 11, Not applicable 6, Phase 4 4, Phase 3 17, Phase 2/3 1, Phase 2 18, Phase 1/2 6, Phase 1 13) 2006: 84 trials (Other 1, Observational 11, Not applicable 7, Phase 4 3, Phase 3 18, Phase 2/3 1, Phase 2 19, Phase 1/2 3, Phase 1 21) 2007: 91 trials (Other 1, Observational 12, Not applicable 7, Phase 4 6, Phase 3 12, Phase 2/3 2, Phase 2 27, Phase 1/2 5, Phase 1 19) 2008: 70 trials (Observational 14, Not applicable 6, Phase 4 6, Phase 3 14, Phase 2/3 1, Phase 2 13, Phase 1/2 5, Phase 1 11) 2009: 66 trials (Other 1, Observational 13, Not applicable 7, Phase 4 3, Phase 3 4, Phase 2/3 3, Phase 2 19, Phase 1/2 2, Phase 1 14) 2010: 72 trials (Observational 15, Not applicable 11, Phase 4 2, Phase 3 9, Phase 2 17, Phase 1/2 6, Phase 1 12) 2011: 63 trials (Observational 11, Not applicable 6, Phase 4 6, Phase 3 8, Phase 2 15, Phase 1/2 6, Phase 1 11) 2012: 59 trials (Observational 10, Not applicable 4, Phase 4 7, Phase 3 15, Phase 2 8, Phase 1/2 7, Phase 1 8) 2013: 72 trials (Observational 11, Not applicable 4, Phase 4 9, Phase 3 10, Phase 2 12, Phase 1/2 5, Phase 1 21) 2014: 73 trials (Observational 9, Not applicable 5, Phase 4 6, Phase 3 13, Phase 2/3 3, Phase 2 15, Phase 1/2 7, Phase 1 15) 2015: 68 trials (Observational 11, Not applicable 6, Phase 4 5, Phase 3 9, Phase 2/3 2, Phase 2 17, Phase 1/2 5, Phase 1 13) 2016: 77 trials (Observational 19, Not applicable 9, Phase 4 5, Phase 3 6, Phase 2/3 1, Phase 2 13, Phase 1/2 8, Phase 1 16) 2017: 75 trials (Observational 13, Not applicable 12, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 16, Phase 1/2 7, Phase 1 15) 2018: 64 trials (Observational 12, Not applicable 8, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 19, Phase 1/2 9, Phase 1 11) 2019: 78 trials (Observational 9, Not applicable 12, Phase 4 2, Phase 3 11, Phase 2 18, Phase 1/2 8, Phase 1 18) 2020: 74 trials (Observational 15, Not applicable 17, Phase 4 4, Phase 3 1, Phase 2/3 1, Phase 2 11, Phase 1/2 6, Phase 1 19) 2021: 89 trials (Observational 22, Not applicable 10, Phase 4 10, Phase 3 6, Phase 2/3 1, Phase 2 14, Phase 1/2 8, Phase 1 18) 2022: 82 trials (Observational 12, Not applicable 7, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 2 21, Phase 1/2 13, Phase 1 17) 2023: 109 trials (Observational 26, Not applicable 15, Phase 4 4, Phase 3 7, Phase 2 13, Phase 1/2 12, Phase 1 32) 2024: 90 trials (Observational 22, Not applicable 20, Phase 4 4, Phase 3 8, Phase 2/3 1, Phase 2 12, Phase 1/2 8, Phase 1 15) 2025: 125 trials (Observational 19, Not applicable 34, Phase 4 7, Phase 3 6, Phase 2/3 3, Phase 2 14, Phase 1/2 16, Phase 1 26)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 94
2025 125
2024 90
2023 109
2022 82
2021 89
2020 74
2019 78
2018 64
2017 75

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 216 trials still running at the 2026-10-09 snapshot; registered median of 32 months across 1,416 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Herpesviridae Infections trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 537
Phase 1/2 197
Phase 2 531
Phase 2/3 31
Phase 3 300
Phase 4 131
Not applicable 308
Observational 372
Expanded access 7
Unknown 1

How many Herpesviridae Infections trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 82
Recruiting 262
Enrolling by invitation 13
Active, not recruiting 98
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Herpesviridae Infections trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 152
National Institute of Allergy and Infectious Diseases (NIAID) 111
GlaxoSmithKline 100
Merck Sharp & Dohme LLC 59
Children's Oncology Group 25

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Herpesviridae Infections? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 214
RITUXIMAB 115
Prednisone 68
Ganciclovir 62

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 116
Etoposid 102
Peripheral blood stem cell transplantation 95
Filgrastime (G-CSF) 92
Vincristina 89

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Herpesviridae Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,522 107
Febrile neutropenia 1,146 81
Neutrophil count decreased 1,055 36
Platelet count decreased 883 36
Sepsis 751 93

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Herpesviridae Infections? (95)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Herpesvirus immunology in solid organ transplant recipients - liver transplant study (HISTORY): a retrospective and prospective observational cohort study. BMC infectious diseases 2023 Yes
Herpes DNAemia and TTV Viraemia in Intensive Care Unit Critically Ill Patients: A Single-Centre Prospective Longitudinal Study. Frontiers in immunology 2021 Yes
Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020 Yes
Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2020 Yes
The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood 2017 Yes

Showing 5 of 95 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages